Recombinant human Integrin alpha V beta 8 (4135-AV) binds recombinant human LAP (246-LP) in a functional ELISA. The estimated Kd for this interaction is < 0.5 nM.
Recombinant Human Integrin alpha V beta 8 Protein, CF Summary
Details of Functionality
Measured by its binding ability in a functional ELISA. Immobilized Recombinant Human Integrin alpha V beta 8 at 2 µg/mL can bind recombinant human Lap with an apparent Kd <0.5 nM.
Source
Chinese Hamster Ovary cell line, CHO-derived human Integrin alpha V beta 8 protein
Human Integrin alpha V (Phe31-Val992) Accession # NP_002201.1
His-Pro
GGGSGGGS
Acidic Tail
Human Integrin beta 8 (Glu43-Arg684) Accession # P26012.1
>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Note
<0.01 EU per 1 μg of the protein by the LAL method.
Applications/Dilutions
Dilutions
Binding Activity
Theoretical MW
110.5 kDa ( alpha V subunit), 75.3 kDa ( beta 8 subunit). Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
SDS-PAGE
130-155 kDa and 85-100 kDa, reducing conditions
Publications
Read Publications using 4135-AV in the following applications:
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
2 weeks, 2 to 8 °C under sterile conditions after reconstitution.
3 months, -20 to -70 °C under sterile conditions after reconstitution.
Buffer
Lyophilized from a 0.2 μm filtered solution in Tris, NaCl and MgCl2.
Purity
>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Reconstitution Instructions
Reconstitute at 100 μg/mL in sterile PBS.
Notes
This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.
Alternate Names for Recombinant Human Integrin alpha V beta 8 Protein, CF
Integrin alpha V beta 8
Background
Integrin alpha V beta 8 is one of five alpha V integrins and the only known beta 8 integrin (1-3). The non-covalent heterodimer of 170 kDa alpha V and ~90 kDa beta 8 integrin type I transmembrane glycoprotein subunits is expressed in yolk sac, placenta, brain perivascular astrocytes, Schwann cells, renal glomerular mesangial cells and pulmonary epithelial cells (3-7). Unlike other alpha V integrins, alpha V beta 8does not appear to assume different activation states, and the cytoplasmic tail does not connect to the cytoskeleton (3, 8). It binds ligands containing an RGD motif, including vitronectin, fibrin and the latency associated peptide (LAP) of the latent TGF-beta complex (7-12). High affinity binding of alpha V beta 8 to LAP allows proteolytic cleavage by MT1-MMP, which releases active TGF-beta . This mechanism differs from that of alpha V beta 6, the other alpha V integrin which can activate TGF-beta from latency through non-proteolytic mechanisms (13). Downstream effects of TGF-beta activation include control of cell growth and associated vascularization (10-13). Deletion of either alpha Vor beta 8 reveals that alpha V beta 8 is required for vascular morphogenesis in the embryonic brain and yolk sac (4, 14, 15). The 962 aa human alpha V extracellular domain (ECD) shares 92-95% aa sequence identity with mouse, rat and cow alpha V, while the 642 aa human beta 8 ECD shares 92%, 92%, 89%, 87% and 87% aa identity with cow, dog, rabbit, mouse and rat beta 8, respectively. The beta 8 ECD of beta 8 shows low (~35%) aa identity with other integrin beta subunits, and the cytoplasmic tail is unlike any other integrin. The alpha V ECD contains an N-terminal beta - propeller structure, followed by domains termed thigh, calf-1 and calf-2 (1). The beta 8 ECD contains a vWFA domain, which interacts with the alpha V beta -propeller to form a binding domain. Each subunit has a transmembrane sequence and a short cytoplasmic tail.
Hynes, R. O. (2002) Cell 110:673.
Suzuki, S. et al. (1987) J. Biol. Chem. 262:14080.
Moyle, M. et al. (1991) J. Biol. Chem. 266:19650.
Zhu, J. et al. (2002) Development 129:2891.
Cambier, S. et al. (2000) Cancer Res. 60:7084.
Lakhe-Reddy, S. et al. (2006) J. Biol. Chem. 281:19688.
Chernousov, M. A. and D. J. Carey (2003) Exp. Cell Res. 291:514.
Nishimura, S. L. et al. (1994) J. Biol. Chem. 269:28708.
Milner, R. et al. (1999) J. Cell Sci. 112:4271.
Cambier, S. et al. (2005) Am. J. Pathol. 166:1883.
Fjellbirkeland, L. et al. (2003) Am. J. Pathol. 163:533.
Araya, J. et al. (2006) Am. J. Pathol. 169:405.
Mu, D. et al. (2002) J. Cell Biol. 157:493.
Proctor, J. M. et al. (2005) J. Neurosci. 25:9940.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
=
÷
Review this Product
Be the first to review our Recombinant Human Integrin alpha V beta 8 Protein, CF and receive a gift card or discount.